Azienda Sanitaria Locale Citta Di Torino
- Address
- lock Available on a paid plan
HIV and Antiretroviral Therapy Research
At Azienda Sanitaria Locale Citta Di Torino, a major focus is HIV care and treatment optimization, with studies in Virus Diseases and Immune System Diseases aimed at improving long-term control of infection and simplifying therapy for people living with HIV-1.
- Switching stable patients to newer antiretroviral combinations to maintain viral suppression
- Testing novel oral regimens for treatment-naïve and treatment-experienced people with HIV-1
- Evaluating safer, more convenient treatment strategies for chronic HIV management
These trials are designed to assess treatment effectiveness, support durable viral control, and expand options for patients with limited or complex prior therapy.
Kidney Disease and Nephrology Studies
The site’s SCDU Nefrologia e Dialisi - CMID department is also active in Reproductive and Urinary Physiological Phenomena research, with studies centered on chronic kidney disease, Immunoglobulin A Nephropathy (IgAN), and rapidly progressive glomerulonephritis.
- Assessing therapies that may preserve kidney function and reduce protein loss in IgAN
- Studying rescue approaches for severe inflammatory kidney disease
- Exploring treatments that may slow worsening kidney disease and related complications
Overall, the research aims to improve kidney protection, evaluate safety, and identify better options for patients with progressive renal disorders.
Cardiovascular and Stroke Prevention Research
Clinical trials in Cardiovascular Diseases at this Turin site include work on preventing ischemic stroke and reducing heart-related events in people with type 2 diabetes and other high-risk conditions.
- Testing new approaches to lower the risk of stroke after a recent cerebrovascular event
- Evaluating therapies that may reduce major cardiovascular complications in high-risk diabetes
- Studying strategies to improve protection against clot-related vascular events
These studies focus on prevention and cardiovascular risk reduction, with the goal of improving outcomes in patients vulnerable to serious vascular disease.
Infectious Disease and Respiratory Infection Trials
Research in Bacterial Infections and Mycoses and Respiratory Tract Diseases includes studies on tuberculosis and severe viral lung infections, reflecting a strong interest in difficult-to-treat infections.
- Examining safer and more effective treatment approaches for tuberculosis
- Testing therapies for hospitalized patients with serious viral lung disease
- Looking at ways to improve infection control and clinical outcomes in severe respiratory illness
These trials are intended to support better infection treatment, improve tolerability, and address high-risk respiratory conditions.
Autoimmune, Viral Hepatitis, and Cancer Research
The site also contributes to broader Immune System Diseases, Virus Diseases, and Neoplasms research, including studies in Systemic Lupus Erythematosus, Chronic Hepatitis D Virus (HDV) Infection, and colorectal cancer.
- Evaluating new options to reduce autoimmune disease activity in lupus
- Studying antiviral approaches for chronic hepatitis D infection
- Comparing treatment strategies for advanced colorectal cancer after prior therapy
Across these areas, the trials aim to improve disease control, test new therapeutic options, and refine care for patients with complex chronic illnesses.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 33 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Gilead Sciences Inc.2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Gilead Sciences Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Citta Di Torino
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Naïve Viremic Persons with HIV-1.( INNOVATE Study) | Viiv Healthcare UK Limited | Phase II | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 33 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bictegravir | 3 | Unknown | 2023-05-17 | 2023-11-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.